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The tools of molecular biology have allowed us to
understand physiologic processes at the level of chem-
ical signals and mediators that alter fundamental cell
function. Part of the molecular biology paradigm is a
shift to experimental models that use manipulation of
phenotype to produce changes in protein composition
that affect cell behavior, even when the protein itself is
difficult to measure or when its effect is so compart-
mentalized that measurement would provide little use-
ful information.
However, for clinicians, the holy grail of molecular
biology is gene therapy. That is, the ability to change
cell phenotype so that a protein product is enhanced or
diminished to achieve a desired physiologic effect.
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The ability to alter cell phenotype by introducing
genetic material has been demonstrated in almost every
organ system. When genetic material is introduced into
rapidly dividing cells or stem cells, there is hope that
the genetic material may become incorporated into the
genome of subsequent cells and be permanently carried
forward. Introducing genetic material into mature and
frequently nonreplicating cells is a much more difficult
task. In contrast to disease states in which a single
enzyme is missing (for example, adenosine deami-
nase), some pathologic conditions require repeated
rather than sustained therapy. Introduction of genetic
material into cells would be a far more effective strate-
gy if the altered phenotype could be controlled with an
“off-on” switch. Lee and his colleagues have admirably
demonstrated this technique in this issue of the Journal.
It is interesting that the protein produced in response to
stimulation of the promoter region of the gene is in
such small quantities that it cannot yet be measured.
However, the effects of the up-regulated protein are
easily measurable in the form of a platelet count. These
studies address one of the important issues in gene
therapy—control of the gene product expressed.1 In
experimental animals, many genes and gene products
of interest to cardiac biologists and pulmonary biolo-
gists have been manipulated. These include the genes
responsible for the defect in cystic fibrosis (CFTR),
angiogenesis (VEGF), the beta receptor (b -AR), genes
regulating the expression of myocardial protective fac-
tors such as heat shock protein (HSP), genes that influ-
ence the inflammatory process in endothelial cells
(NFKB), and genes that may prolong transplant graft
survival (TGF-b 1).2
These laboratory experiments have come to fruition
in clinical trials experimenting both with the protein
products that govern angiogenesis and with gene strate-
gies to up-regulate angiogenic growth factors. How-
ever, a number of problems remain. In mature cells, it
appears inexorable that the vector genome (synony-
mous with the genetic material producing the designed
alteration in phenotype) diminishes. Mechanisms for
gene destruction may be inflammatory, the normal
process of degradation and turnover of nuclear proteins
and bases, gene products that are recognized as “for-
eign” with time, and the attachment of the transfected
material to chromosomal locations where the effect is
blunted. There is inadequate understanding of factors
controlling long-term expression of gene actions deter-
mined by complex interactions between promoters and
enhancers within the cell, some of which may be locat-
ed at sites distant from the genetic material.3
Lee and his colleagues have not offered a solution to
the problem of gene therapy, and the use of gene
enhancers has been successfully demonstrated in other
organ systems. Ultimately, the coming together of an
entire science facilitating control of gene expression
will perhaps make gene therapy in mature cells a reali-
ty. For the time being, let us regard this contribution as
another “baby step” toward this ultimate goal.
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